Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Regenerative Medical Technology Group 3-Year RORE %?
Regenerative Medical Technology GroupRMTG +3.55% 3-Year RORE % is -10.06 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 1,291 Biotechnology companies, Regenerative Medical Technology Group ranks better than 51.36% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Regenerative Medical Technology Group's 3-Year RORE % for the quarter that ended in Mar. 2026 was -10.06%.
RMTG's 3-Year RORE % is ranked better than 51.36% of 1291
companies
in the Biotechnology industry
Industry Median: -11.34
vs RMTG: -10.06
Regenerative Medical Technology Group (OTCPK:RMTG) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Regenerative Medical Technology Group 3-Year RORE % Related Terms
Regenerative Medical Technology Group 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group 3-Year RORE % Chart
RMTG vs PTIX, CERO, EMMA: 3-Year RORE % Comparison
For the Biotechnology subindustry, Regenerative Medical Technology Group's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group 3-Year RORE % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Regenerative Medical Technology Group (RMTG) has a 3-Year RORE % of -10.06 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Regenerative Medical Technology Group and its competitors. According to the industry distribution chart, Regenerative Medical Technology Group ranks #628 out of 1291 companies in the Biotechnology industry, placing it in the top 48.6%.
Is Regenerative Medical Technology Group's 3-Year RORE % too high?
Regenerative Medical Technology Group's current 3-Year RORE % is -10.06. Based on the distribution chart, Regenerative Medical Technology Group ranks #628 out of 1291 companies in the Biotechnology industry, which is above the industry midpoint.
How does Regenerative Medical Technology Group's 3-Year RORE % compare to PTIX and CERO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #628 out of 1291 companies for 3-Year RORE %. This puts Regenerative Medical Technology Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Regenerative Medical Technology Group and its competitors. Regenerative Medical Technology Group's current 3-Year RORE % is -10.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.06, compared to a current price of $0.07 — trading 21.5% above its estimated fair value. The current 3-Year RORE % is -10.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current 3-Year RORE % is -10.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 
